N't write (Don t write nea ~ery part) this part) re a mid-level manager a( ‘GoodLife Pharma, ” compagy in India. Afier years of research and development, the company Is on thel cusp of launching a revolution yew drug( ‘Reviv K which promises to significantly improve the lives of s suffering from a debilitating chronic illnesy. The drug is projected to be ckbuster, general billions) in revenue nd potentially saving countless livest You've b li yes Youve been an integral part of the Revivol (eam), and its success could significantly boost your career prospects. However, just weeks before the scheduled launch, you stumble upon | disturbing evidence suggesting that Revivol may have serious, potentially fatal, side effects in a small percentage of patients. These side effects were not adequately disclosed in the initial clinical trial reports, and further investigation reveals that some data points indicating adverse reactions were deliberately omitted from the final report Submitted to the regulatory authorities. You are deeply troubled by this discovery. You understand that the drug is likely to receive approval based on the existing data, and the company is already heavily inyested_in its marketing and_laynch. However, the potential harm to patients weighs heavily on your conscience. To add to the complexity, you discover that your direct superior was aware of the data discrepancies and chose to ignore them. Confronting them directly might lead to retaliation, jeopardizing your job and career. You’re also the sole breadwinner for your family, and losing your job would have devastating financial consequences. =— leading pharmaceutical pace. Wl dbonabansdtchalr a) What are the ethical dilemmas faced by the manager in this scenario? oe ———$$$—$—_———————— b) What will be your course of action and why? c) How could stronger corporate governance mechanisms have prevented or mitigated this situation?

Topper: Shivansh Tripathi · AIR 293 · 2025 · Page 45